**Supplemental Material**

Table of Contents:

Supplemental Table 1. Patient characteristics and comparisons for all groups (2 risk allele, 1 risk allele, 0 risk alleles and non-Black patients).

| | Black Patients with MN | | | |
|---|---|---|---|---|
| | 2 *APOL1* Risk Alleles | 1 *APOL1* Risk Alleles | 0 *APOL1* Risk Alleles | Non-Black Patients |
| | n=16 | n=49 | n=53 | n=573 |
| Age at diagnosis (years), Median(IQR) | 41(34, 51) | 52(37, 58) | 44(34, 57) | 50(37, 62) |
| Female Sex n(%) | 9(56%) | 30(61%) | 28(53%) | 211(37%) |
| Follow-up time(mo), Median(IQR) | 44(27, 121) | 54(31, 82) | 48(25, 78) | 52(32, 79) |
| eGFR at diagnosis, mL/min/1.73m$^2$, Median(IQR) | 83.2(59.3, 100.4) | 78(60.1, 100.2) | 82 (51.8, 115.8) | 84.5(59.4, 103.7) |
| Kidney Failure n(%) | 5(31.25%) | 5(10.2%) | 6(11.32%) | 31(5.41%) |
| Dialysis | 4(25%) | 4(8.16%) | 5(9.43%) | 22(3.84%) |
| Transplant | 2(12.5%) | 0(0.00%) | 2(3.77%) | 7(1.22%) |
| GFR<15 | 0(0.00%) | 1(2.04%) | 0(0.00%) | 4(0.7%) |
| Death (n, %) | 1(6.25%) | 1(2.04%) | 1(1.89%) | 10(1.75%) |

*comparing Black patients with 2, 1 or 0 APOL1 Risk Alleles

**comparing non-black patients, 2, 1, 0 APOL1 Risk Alleles

Supplemental Table 2. Kidney Biopsy Findings

| | **2 APOL1 Risk Alleles (n=7)** | **1 APOL1 Risk Alleles (n=23)** | **0 APOL1 Risk Alleles (n=16)** |
|---|---|---|---|
| **Total number of glomeruli per sample (median, IQR)** | 8(6.0, 22.0) | 18(13.0, 24.0) | 24(18.5, 34.5) |
| **Cases with global glomerular sclerosis, n (%)** | 5(71%) | 16(70%) | 10(63%) |
| **Mean degree of global sclerosis (0-4+)** | 1.6 | 0.9 | 0.9 |
| **Cases with capillary wall changes seen with arterionephrosclerosis, n (%)** | 4 (57%) | 12 (52%) | 8 (50%) |
| **Cases with Segmental glomerular sclerosis lesions present, n (%)** | 5(71%) | 11(48%) | 6 (38%) |
| **Cases with diagnostic FSGS lesions present, n (%)** | 5(71%) | 11(48%) | 5(31%) |
| NOS = all others | 3(43%) | 5(22%) | 1(6%) |
| Perihilar = ≥50% of segmental lesions perihilar | 1(14%) | 1(4%) | 0(0.0%) |
| Tip = tip lesion with no collapsing or perihilar lesions | 0(0.0%) | 5(22%) | 4(25%) |
| Collapsing | 1(14%) | 0(0.0%) | 0(0.0%) |
| **Cases with Interstitial fibrosis & tubular atrophy (IFTA) present, n (%)** | 7(100%) | 16(70%) | 11(69%) |
| **Mean degree of IFTA (0-4+)** | 2.0 | 0.9 | 1.1 |
| **Arteriosclerosis, n (%)** | | | |
| Intima with fibrosis <25% the thickness of the media | 1(14%) | 13(57%) | 10(63%) |
| Intima with fibrosis ≥25% the thickness of the media | 4(57%) | 8(35%) | 5(31%) |
| Not technically adequate for scoring | 2(29%) | 2(9%) | 1(6%) |
| **Mean degree of arteriosclerosis (0-4+)** | 2.0 | 1.1 | 1.1 |
| **Arteriolar hyalinosis or arteriolosclerosis, n (%)** | | | |
| No arteriolar hyalinosis | 2(29%) | 16(70%) | 8(50%) |
| Intima with fibrosis <25% the thickness of the media | 3(43%) | 3(13%) | 5(31%) |
| Intima with fibrosis ≥25 - 50% the thickness of the media | 1(14%) | 3(13%) | 2(13%) |
| Not technically adequate for scoring | 1(14%) | 1(4%) | 1(6%) |
| **Mean degree of arteriolar hyalinosis (0-4+)** | 0.8 | 0.4 | 0.7 |

Supplemental Table 3. eGFR slope comparisons in over follow up years

| Groups comparisons | | Time since disease onset (years) | Estimate | Standard | 95% CI | | P value |
|---|---|---|---|---|---|---|---|
| Group1 | Group2 | | | *error* | Lower | Upper | |
| **0 APOL1 Risk Alleles** | **1 APOL1 Risk Alleles** | 0.1 | -0.9 | 3.8 | -8.3 | 6.6 | 0.8 |
| **0 APOL1 Risk Alleles** | **2 APOL1 Risk Alleles** | 0.1 | 5.5 | 5.8 | -5.9 | 16.9 | 0.3 |
| **0 APOL1 Risk Alleles** | **Non-Black Patients** | 0.1 | 4.1 | 2.8 | -1.4 | 9.6 | 0.1 |
| **1 APOL1 Risk Alleles** | **2 APOL1 Risk Alleles** | 0.1 | 6.4 | 5.8 | -5.1 | 17.8 | 0.3 |
| **1 APOL1 Risk Alleles** | **Non-Black Patients** | 0.1 | 5.0 | 2.9 | -0.7 | 10.6 | 0.1 |
| **2 APOL1 Risk Alleles** | **Non-Black Patients** | 0.1 | -1.4 | 5.3 | -11.7 | 8.8 | 0.8 |
| **0 APOL1 Risk Alleles** | **1 APOL1 Risk Alleles** | 0.3 | -1.0 | 3.8 | -8.4 | 6.4 | 0.8 |
| **0 APOL1 Risk Alleles** | **2 APOL1 Risk Alleles** | 0.3 | 6.9 | 5.7 | -4.3 | 18.2 | 0.2 |
| **0 APOL1 Risk Alleles** | **Non-Black Patients** | 0.3 | 3.8 | 2.8 | -1.6 | 9.3 | 0.2 |
| **1 APOL1 Risk Alleles** | **2 APOL1 Risk Alleles** | 0.3 | 7.9 | 5.8 | -3.4 | 19.2 | 0.2 |
| **1 APOL1 Risk Alleles** | **Non-Black Patients** | 0.3 | 4.8 | 2.9 | -0.8 | 10.4 | 0.1 |
| **2 APOL1 Risk Alleles** | **Non-Black Patients** | 0.3 | -3.1 | 5.2 | -13.3 | 7.1 | 0.5 |
| **0 APOL1 Risk Alleles** | **1 APOL1 Risk Alleles** | 0.5 | -1.3 | 3.7 | -8.6 | 6.0 | 0.7 |
| **0 APOL1 Risk Alleles** | **2 APOL1 Risk Alleles** | 0.5 | 9.8 | 5.6 | -1.2 | 20.9 | 0.1 |
| **0 APOL1 Risk Alleles** | **Non-Black Patients** | 0.5 | 3.3 | 2.7 | -2.1 | 8.7 | 0.2 |
| **1 APOL1 Risk Alleles** | **2 APOL1 Risk Alleles** | 0.5 | 11.1 | 5.7 | 0.0 | 22.3 | 0.1 |
| **1 APOL1 Risk Alleles** | **Non-Black Patients** | 0.5 | 4.6 | 2.8 | -0.9 | 10.1 | 0.1 |
| **2 APOL1 Risk Alleles** | **Non-Black Patients** | 0.5 | -6.5 | 5.1 | -16.5 | 3.4 | 0.2 |
| **0 APOL1 Risk Alleles** | **1 APOL1 Risk Alleles** | 1.0 | -1.8 | 3.8 | -9.2 | 5.5 | 0.6 |
| **0 APOL1 Risk Alleles** | **2 APOL1 Risk Alleles** | 1.0 | 15.7 | 5.7 | 4.6 | 26.9 | 0.0 |
| **0 APOL1 Risk Alleles** | **Non-Black Patients** | 1.0 | 2.3 | 2.8 | -3.1 | 7.7 | 0.4 |
| **1 APOL1 Risk Alleles** | **2 APOL1 Risk Alleles** | 1.0 | 17.5 | 5.7 | 6.3 | 28.8 | 0.0 |
| **1 APOL1 Risk Alleles** | **Non-Black Patients** | 1.0 | 4.1 | 2.8 | -1.5 | 9.7 | 0.1 |
| **2 APOL1 Risk Alleles** | **Non-Black Patients** | 1.0 | -13.4 | 5.1 | -23.5 | -3.4 | 0.0 |
| **0 APOL1 Risk Alleles** | **1 APOL1 Risk Alleles** | 2.0 | -2.9 | 4.3 | -11.4 | 5.6 | 0.5 |
| **0 APOL1 Risk Alleles** | **2 APOL1 Risk Alleles** | 2.0 | 27.4 | 6.7 | 14.3 | 40.5 | <.0001 |
| **0 APOL1 Risk Alleles** | **Non-Black Patients** | 2.0 | 0.2 | 3.2 | -6.0 | 6.5 | 0.9 |
| **1 APOL1 Risk Alleles** | **2 APOL1 Risk Alleles** | 2.0 | 30.3 | 6.7 | 17.2 | 43.5 | <.0001 |
| **1 APOL1 Risk Alleles** | **Non-Black Patients** | 2.0 | 3.1 | 3.3 | -3.2 | 9.5 | 0.3 |
| **2 APOL1 Risk Alleles** | **Non-Black Patients** | 2.0 | -27.2 | 6.0 | -39.0 | -15.4 | <.0001 |
| **0 APOL1 Risk Alleles** | **1 APOL1 Risk Alleles** | 4.0 | -5.1 | 6.6 | -18.1 | 7.9 | 0.4 |
| **0 APOL1 Risk Alleles** | **2 APOL1 Risk Alleles** | 4.0 | 50.9 | 10.6 | 30.0 | 71.7 | <.0001 |
| **0 APOL1 Risk Alleles** | **Non-Black Patients** | 4.0 | -3.9 | 4.9 | -13.6 | 5.8 | 0.4 |
| **1 APOL1 Risk Alleles** | **2 APOL1 Risk Alleles** | 4.0 | 56.0 | 10.6 | 35.2 | 76.8 | <.0001 |
| **1 APOL1 Risk Alleles** | **Non-Black Patients** | 4.0 | 1.2 | 4.9 | -8.5 | 10.9 | 0.8 |
| **2 APOL1 Risk Alleles** | **Non-Black Patients** | 4.0 | -54.8 | 9.6 | -73.7 | -35.9 | <.0001 |
| **0 APOL1 Risk Alleles** | **1 APOL1 Risk Alleles** | 8.0 | -9.5 | 12.6 | -34.2 | 15.3 | 0.5 |
| **0 APOL1 Risk Alleles** | **Non-Black Patients** | 8.0 | -12.1 | 9.5 | -30.7 | 6.4 | 0.2 |
| **1 APOL1 Risk Alleles** | **Non-Black Patients** | 8.0 | -2.7 | 9.3 | -20.9 | 15.6 | 0.8 |
| **0 APOL1 Risk Alleles** | **1 APOL1 Risk Alleles** | 16.0 | -18.2 | 25.4 | -68.0 | 31.6 | 0.5 |
| **0 APOL1 Risk Alleles** | **Non-Black Patients** | 16.0 | -28.6 | 19.1 | -66.0 | 8.8 | 0.1 |
| **1 APOL1 Risk Alleles** | **Non-Black Patients** | 16.0 | -10.4 | 18.8 | -47.2 | 26.4 | 0.6 |

Supplemental Table 4. Unadjusted and adjusted eGFR slopes.

| | Model 0: | Model 1: | Model 2: | Model 3: | Model 4: |
|---|---|---|---|---|---|
| **Risk Groups** | **unadjusted** | **adjusted by age *** | **adjusted by sex** | **adjusted by baseline eGFR*** | **adjusted by age*, sex & eGFR*** |
| **2 APOL1 Risk alleles (n=16)** | -15.9(2.5) | -15.9(2.5) | -15.9(2.5) | -15.8(2.4) | -15.6 (2.4) |
| **1 APOL1 Risk alleles (n=53)** | -2.8(1.2) | -2.8(1.2) | -2.8(1.2) | -3.0(1.1) | -3.0(1.1) |
| **0 APOL1 Risk alleles (n=49)** | -4.2(1.2) | -4.2(1.2) | -4.2(1.2) | -4.1(1.2) | -4.0(1.2) |
| **Non-Black MN (n=572)** | -2.0(0.4) | -2.0(0.4) | -2.0(0.4) | -2.0(0.4) | -2.0(0.4) |

Supplemental Table 5. Hazard ratio for risk of kidney failure.

| **HR for ESKD** | **Model 0: Unadjusted** | **Model 1: Adjusted by age*** | **Model 2: Adjusted by sex** | **Model 3: Adjusted by eGFR*** | **Model 4: Adjusted by age*, sex & eGFR*** |
|---|---|---|---|---|---|
| APOL1 2 vs 0 | 1.7(0.5, 6.0) | 1.7(0.5, 6.2) | 1.8 (0.5, 6.3) | 2.8(0.7, 11.8) | 3.4(0.8, 14.6) |
| APOL1 2 vs 1 | 1.9(0.5, 7.3) | 2.0(0.5, 7.7) | 1.9(0.5, 7.2) | 3.0(0.7, 12.5) | 3.5(0.8, 14.9) |
| APOL1 2 vs Non Black | 3.8 (1.4, 10.8) | 4.0(1.4, 11.4) | 4.2(1.5, 12.0) | 7.2(2.1, 24.8) | 8.1(2.3, 27.8) |
| APOL1 0 vs Non Black | 2.3(0.9, 5.4) | 2.3 (1.0, 5.6) | 2.4(1.0, 5.7) | 2.6 (1.0, 6.9) | 2.4(0.9, 6.5) |
| APOL1 1 vs Non Black | 2.0(0.8, 5.1) | 2.0 (0.8, 5.1) | 2.2 (0.8, 5.8) | 2.5(0.9, 6.6) | 2.3(0.9, 6.3) |
| APOL1 1 vs 0 | 1.1(0.4, 3.8) | 1.2(0.4, 3.8) | 0.6(0.2 2.0) | 11(0.3, 3.7) | 1.0(0.3, 3.5) |

Supplemental Table 6. Clinical characteristics of CureGN and GDCN Cohorts.

| | **CureGN Cohort** | **GDCN Cohort** |
|---|---|---|
| **Total n** | N=525 | N=165 |
| **Age at disease Onset, median (IQR)** | 51(36, 62) | 47.3(37, 56) |
| **Sex, female (n, %)** | 208(40%) | 70(42%) |
| **Black race (n, %)** | 68(13%) | 50(31%) |

Supplemental Figure 1. eGFR slope for all groups (LS mean and SE shown)




Supplemental Figure 2. Kidney Survival in patients with MN by all groups (2 risk allele, 1 risk allele, 0 risk alleles and 3 (non- Black patients))



Contributors to CureGN Consortium.

**CureGN Collaborators**

The CureGN Consortium members listed below, from within the four Participating Clinical Center networks and Data Coordinating Center, are acknowledged by the authors as Collaborators.
**CureGN Principal Investigators; *CureGN Site Principal Investigators; #CureGN Lead Coordinators.

**CureGN Participating Clinical Centers (PCC) through Columbia University:**

*Columbia University, New York, NY, US*: Wooin Ahn, Gerald Appel, Paul Appelbaum, Revekka Babayev, Andrew Bomback, Pietro Canetta, Brenda Chan, Vivette Denise D'Agati, Samitri Dogra, Hilda Fernandez, Ali Gharavi**, William Hines, Syed Ali Husain, Namrata Jain, Krzysztof Kiryluk, Fangming Lin, Maddalena Marasa#, Glen Markowitz, Hila Milo Rasouly, Sumit Mohan, Nicola Mongera, Jordan Nestor, Thomas Nickolas, Jai Radhakrishnan, Maya Rao, Simone Sanna-Cherchi, Shayan Shirazian, Michael Barry Stokes, Natalie Uy, Anthony Valeri, Natalie Vena

*University of Warsaw, Warszawa, Poland:* Bartosz Foroncewicz, Barbara Moszczuk, Krzysztof Mucha*, Agnieszka Perkowska-Ptasińska

*Gaslini Children's Hospital, Genoa, Italy:* Gian Marco Ghiggeri*, Francesca Lugani

**CureGN Participating Clinical Centers (PCC) through the Pediatric Nephrology Research Consortium:**

*Arkana Laboratories, Little Rock, AR, USA*: Josephine Ambruzs, Helen Liapis

*Children's Hospital of Michigan, Detroit, MI, USA*: Rossana Baracco, Amrish Jain*

*Children's Hospital of New Orleans/ LSU Health, New Orleans, LA, USA*: Isa Ashoor, Diego Aviles*

*Children's Mercy Hospital, Kansas City, MO, USA*: Tarak Srivastava*

*Children's National Medical Center, Washington DC, USA*: Sun-Young Ahn*

*Cincinnati Children's Hospital Cincinnati, OH, USA*: Prasad Devarajan, Elif Erkan*, Donna Claes, Hillarey Stone

*Connecticut Children's Medical Center, Hartford, CT, USA*: Sherene Mason*

*Duke Children's Hospital Medical Center, Durham, NC, USA*: Rasheed Gbadegesin*

*East Carolina University Brody School of Medicine, Greenville, NC, USA*: Liliana Gomez-Mendez*

*Emory University, Atlanta, GA, USA*: Larry Greenbaum**, Chia-shi Wang, Hong (Julie) Yin

*Helen DeVos Children's Hospital, Grand Rapids, MI, USA*: Yi Cai*, Goebel Jens, Julia Steinke

*Levine Children's Hospital/Atrium Health, Charlotte, NC, USA*: Donald Weaver*

*Lurie Children's Hospital, Chicago IL, USA*: Jerome Lane*

*Mayo Clinic, Rochester, MN, USA*: Carl Cramer*

*Medical College of Wisconsin, Milwaukee, WI, USA*: Cindy Pan, Neil Paloian, Rajasree Sreedharan*

*Medical University of South Carolina, Charleston SC, USA*: David Selewski, Katherine Twombley*

*Nationwide Children's Hospital, Columbus, OH, USA*: Corinna Bowers#, Mary Dreher# Mahmoud Kallash*, John Mahan, Samantha Sharpe#, William Smoyer**

*Oregon Health and Science University, Portland, OR, USA*: Amira Al-Uzri*, Sandra Iragorri

*Riley Children's Hospital, Indianapolis, IN, USA*: Myda Khalid*

*Cardinal Glennon Children's Medical Center/ St. Louis University, St. Louis, MO, USA*: Craig Belsha*

*Texas Children's Hospital, Houston, TX, USA*: Joseph Alge*, Michael Braun, AC Gomez, Scott Wenderfer*

*Texas Tech Health Sciences Center, Amarillo, TX, USA*: Tetyana Vasylyeva*

*Children's of Alabama, University of Alabama, Birmingham, AL, USA*: Daniel Feig*

*University of Colorado Children's Hospital, Colorado, Aurora, CO, USA*: Gabriel Cara Fuentes, Melisha Hannah*

*University of Iowa Children's Hospital, Iowa City, IA, USA*: Carla Nester*

*University of Kentucky, Lexington, KY, USA*: Aftab Chishti*

*University of Louisville, Louisville, KY, USA*: Jon Klein**

*Holtz Medical Center, University of Miami, Miami, FL, USA*: Chryso Katsoufis, Wacharee Seeherunvong*
*University of Minnesota Children's Hospital, Minneapolis, MN, USA*: Michelle Rheault*
*University of New Mexico Health Sciences Center, Albuquerque, NM, USA*: Craig Wong*
*University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA*: Nisha Mathews*
*University of Virginia, Charlottesville, VA, USA*: John Barcia*, Agnes Swiatecka-Urban
*University of Wisconsin, Madison, WI, USA*: Sharon Bartosh*
*Vanderbilt Children's Hospital, Nashville TN, USA*: Tracy Hunley*
*Washington University in St. Louis, St. Louis, MO, USA*: Vikas Dharnidharka*, Joseph, Gaut

**CureGN Participating Clinical Centers (PCC) through the University of North Carolina:**
*Hôpital Maisonneuve-Rosemont, Montreal, Canada*: Louis-Philippe Laurin*, Virginie Royal
*Medical University of South Carolina, Charleston, SC, USA*: Anand Achanti, Milos Budisavljevic*, Sally Self
*Northwestern University, Chicago, IL, USA*: Cybele Ghossein, Yonatan Peleg, Shikha Wadhwani*
*Ohio State University, Columbus, OH, USA*: Salem Almaani, Isabelle Ayoub, Tibor Nadasdy, Samir, Parikh, Brad Rovin*
*University of Chicago, Chicago, IL, USA*: Anthony Chang
*University of Alabama at Birmingham, Birmingham, AL, USA*: Huma Fatima, Bruce Julian, Jan Novak, Matthew Renfrow, Dana Rizk*
*University of North Carolina Kidney Center, Chapel Hill, NC, USA*: Dhruti Chen, Vimal Derebail, Ronald Falk**, Keisha Gibson, Dorey Glenn, Susan Hogan, Koyal Jain, J. Charles Jennette, Amy Mottl*, Caroline Poulton[#], Manish Kanti Saha
*Vanderbilt University, Nashville, TN, USA*: Agnes Fogo, Neil Sanghani*
*Virginia Commonwealth University, Richmond, VA, USA*: Jason Kidd*, Selvaraj Muthusamy

**CureGN Participating Clinical Centers (PCC) through the University of Pennsylvania:**
*MetroHealth Medical Center/Case Western Reserve University, Cleveland, OH, USA*: Jeffrey Schelling*
*Cedars-Sinai Health System, Los Angeles, CA, USA*: Jean Hou
*Children's Hospital of LA, Los Angeles, CA, USA*: Kevin Lemley*, Warren Mika, Pierre Russo
*Children's Hospital of Philadelphia, Philadelphia, PA, USA*: Michelle Denburg, Amy Kogon, Kevin Meyers*, Madhura Pradhan
*Cleveland Clinic, Cleveland, OH, CA*: Raed Bou Matar*, John O'Toole*, John Sedor*
Cohen Children's Medical Center, New Hyde Park, NY, USA: Christine Sethna*, Suzanne Vento [#]
*Johns Hopkins University, Baltimore, MD, USA*: Mohamed Atta, Serena Bagnasco, Alicia Neu, John Sperati*
*Lundquist Institute at Harbor-UCLA Medical Center, Torrance, CA, USA*: Sharon Adler*, Tiane Dai, Ram Dukkipati
*Mayo Clinic, Rochester, MN, USA*: Fernando Fervenza*, Sanjeev Sethi
*Montefiore Medical Center, The Bronx, New York, NY, USA*: Frederick Kaskel, Kaye Brathwaite, Kimberly Reidy*
*New York University, New York, NY, USA*: Joseph Weisstuch, Ming Wu, Olga Zhdanova
*NIDDK, Bethesda, MD, USA*: Jurgen Heymann, Jeffrey Kopp*, Meryl Waldman, Cheryl Winkler
*Spokane Providence Medical Center, Spokane, WA, USA*: Katherine Tuttle*
*Stanford University, Palo Alto, CA, USA*: Jill Krissberg, Richard Lafayette*, Kamal Fahmeedah, Elizabeth Talley
*Sunnybrook Health Sciences Centre, Toronto, Canada*: Michelle Hladunewich*
*The Hospital for Sick Children, Toronto, Canada*: Rulan Parekh*
*University Health Network, Toronto, Canada*: Carmen Avila-Casado, Daniel Cattran*, Reich Heather, Philip Boll
*University of Miami, Miami, FL, USA*: Yelena Drexler, Alessia Fornoni*

*University of Michigan, Ann Arbor, MI, USA*: Patrick Gipson*, Jeffrey Hodgin, Andrea Oliverio
*University of Pennsylvania, Philadelphia, PA, USA*: Jon Hogan, Lawrence Holzman**, Matthew Palmer, Gaia Coppock
*University of Pittsburgh School of Medicine, Pittsburgh, PA, USA*: Blaise Abromovitz*, Michael Mortiz*
*University of Washington, Seattle, WA, USA*: Charles Alpers, J. Ashley Jefferson*
*UT Southwestern, Dallas, TX, USA*: Elizabeth Brown, Kamal Sambandam*, Bethany Roehm

**Data Coordinating Center (DCC):**
*Arbor Research Collaborative for Health, Ann Arbor, MI, USA*: Bruce Robinson**, Abigail Smith
*Cedar Sinai Medical Center, Los Angeles, CA, USA*: Cynthia Nast
*Duke University, Durham, NC, USA*: Laura Barisoni
*University of Michigan, Ann Arbor, MI, USA*: Brenda Gillespie**, Debbie Gipson**, Matthias Kretzler, Laura Mariani**

**Steering Committee Chair:** Lisa M. Guay-Woodford, Children's National Hospital, Washington DC, USA